Latest Medicinal Cannabis News

Bioxyne Limited has posted a record $17.2 million in quarterly revenue for Q2 FY26, driven by strong growth in its cannabis and psychedelics segments alongside strategic international expansions.

Little Green Pharma Ltd has agreed to acquire Cannatrek Ltd in a transformational merger that will create a leading vertically integrated medicinal cannabis group across Australia and Europe. The deal combines cultivation, manufacturing, distribution, clinics, and digital health platforms under one roof, positioning the combined entity for accelerated growth.

ECS Botanics reports a $218k positive operating cash flow in Q2 FY26, driven by strong B2C growth and new product launches. The company also secured $1.95 million in funding to fuel European expansion and product development.

Little Green Pharma welcomes a landmark US Executive Order directing cannabis rescheduling, a move poised to reshape the global medicinal cannabis landscape.

Cann Group Limited has launched a comprehensive suite of option offers aimed at raising incremental capital, subject to shareholder approval at a December 23 meeting. The prospectus outlines potential dilution and financial impacts as the company seeks to strengthen its balance sheet.

Epsilon Healthcare Limited has unveiled a comprehensive pre-reinstatement disclosure, highlighting improved financial health and a strategic growth plan focused on operational stability and expansion.

ECS Botanics is strategically preparing for entry into the US medicinal cannabis market, leveraging its EU-GMP certification and proprietary genetics amid evolving regulatory landscapes.

Bioxyne Limited has secured a pioneering manufacturing and supply agreement to enter the emerging medicinal cannabis markets of Costa Rica and Panama, positioning itself as a first mover with promising revenue potential.

ECS Botanics is set to launch AVANI AVA, a new medicinal cannabis range specifically designed for women’s health, aiming to capture a growing market segment with targeted formulations.

Cann Group Limited has announced a dramatic 81% reduction in core debt alongside a strategic pivot to higher-margin flower products, positioning the company for its first EBITDA-positive year in FY26.

Little Green Pharma Ltd reported a 9.6% revenue increase to $19.2 million and slashed its net loss by 73% in the half-year ending September 2025, driven by strong growth in European medicinal cannabis markets.

ECS Botanics has achieved a milestone with direct-to-consumer sales exceeding 60% of total revenue, driven by the launch of innovative sugar-free THC gummies and a strategic distribution partnership.